Chakroborty, A.; Pritchard, D.R.; Bouillon, M.E.; Cervi, A.; Kraehenbuehl, R.; Wild, C.; Fenn, C.; Holdsworth, P.; Capner, C.; Padalino, G.;
et al. Modified Hederagenin Derivatives Demonstrate Ex Vivo Anthelmintic Activity against Fasciola hepatica. Pharmaceutics 2023, 15, 1869.
https://doi.org/10.3390/pharmaceutics15071869
AMA Style
Chakroborty A, Pritchard DR, Bouillon ME, Cervi A, Kraehenbuehl R, Wild C, Fenn C, Holdsworth P, Capner C, Padalino G,
et al. Modified Hederagenin Derivatives Demonstrate Ex Vivo Anthelmintic Activity against Fasciola hepatica. Pharmaceutics. 2023; 15(7):1869.
https://doi.org/10.3390/pharmaceutics15071869
Chicago/Turabian Style
Chakroborty, Anand, Deiniol R. Pritchard, Marc E. Bouillon, Anna Cervi, Rolf Kraehenbuehl, Charlotte Wild, Caroline Fenn, Peter Holdsworth, Colin Capner, Gilda Padalino,
and et al. 2023. "Modified Hederagenin Derivatives Demonstrate Ex Vivo Anthelmintic Activity against Fasciola hepatica" Pharmaceutics 15, no. 7: 1869.
https://doi.org/10.3390/pharmaceutics15071869
APA Style
Chakroborty, A., Pritchard, D. R., Bouillon, M. E., Cervi, A., Kraehenbuehl, R., Wild, C., Fenn, C., Holdsworth, P., Capner, C., Padalino, G., Forde-Thomas, J. E., Payne, J., Smith, B. G., Fisher, M., Lahmann, M., Baird, M. S., & Hoffmann, K. F.
(2023). Modified Hederagenin Derivatives Demonstrate Ex Vivo Anthelmintic Activity against Fasciola hepatica. Pharmaceutics, 15(7), 1869.
https://doi.org/10.3390/pharmaceutics15071869